Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line
NCT02962388 · French Innovative Leukemia Organisation · PHASE2/PHASE3 · terminated · last registry update 2021-06-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “not enough recruitment” | – | Registry record, French Innovative Leukemia Organisation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDE3A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-05-24Phase 3 first posted: Taipei Medical University Hospital, Pu Yang Wan Wu Tang plus Pentoxifylline + Pentoxifylline (NCT05387187)
- 2022-03-17Phase 3 first posted: Al-Azhar University, combination of Pentoxifylline 400 MG and Folic Acid + folic acid (NCT05284656)
- 2022-03-17Phase 3 first posted: Al-Azhar University, pentoxifylline (Trental SR®) (NCT05284448)
- 2022-02-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Levosimendan + PLACEBO (NCT05233202)
- 2022-01-13Also stopped (terminated): Rijnstate Hospital, Enoximone (NCT04420455)
- 2022-01-12Phase 3 first posted: Ain Shams University, Pentoxifylline + Paclitaxel (NCT05189535)
- 2021-11-19Results posted on the registry: Incyte Corporation, Ruxolitinib + Anagrelide (NCT03123588)
- 2021-11-19Also stopped (terminated): Incyte Corporation, Ruxolitinib + Anagrelide (NCT03123588)
- 2021-11-05Results posted on the registry: MediciNova, Placebo (for MN-166) + MN-166 (NCT02238626)
- 2021-10-21Also stopped (terminated): Terence J. Coderre, Topical Solution + Placebos (NCT03342950)
- 2021-10-07Results posted on the registry: University of California, Los Angeles, Ibudilast (NCT03489850)
- 2021-08-31Results posted on the registry: Orion Corporation, Orion Pharma, Levosimendan + Placebo for levosimendan (NCT03505021)
- 2021-07-20Results posted on the registry: Novartis Pharmaceuticals, Best Available Therapy + Ruxolitinib (NCT02038036)
- 2021-05-07Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Part A: RPL554 + Part B: RPL554 (NCT04027439)
- 2021-02-02Also stopped (withdrawn): MetroHealth Medical Center, Pentoxifylline + Placebos (NCT03859570)
- 2021-01-28Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Levosimendan + Placebo of Levosimendan (NCT04728932)
- 2020-12-10Results posted on the registry: Mack Mitchell, Anakinra + Pentoxifylline (NCT01809132)
- 2020-11-17Phase 3 first posted: Cambridge University Hospitals NHS Foundation Trust, Ibudilast + Matching placebo (NCT04631471)
- 2020-10-28Results posted on the registry: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium + Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium (NCT03937479)
- 2020-09-09Phase 3 first posted: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04542057)
- 2020-09-02Phase 3 first posted: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Ensifentrine + Placebo (NCT04535986)
- 2020-07-28Results posted on the registry: MediciNova, ibudilast + Placebo oral capsule (NCT01982942)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision